NCT00055640View on ClinicalTrials.gov

Molecular Risk Assessment in Planning Treatment for Patients With Non-Hodgkin's Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

October 31, 2002

Primary Completion Date

April 30, 2005

Study Completion Date

March 31, 2006

Conditions
Lymphoma
Interventions
BIOLOGICAL

rituximab

Rituximab IV over 3-6 hours.Treatment repeats every 21 days for 3-8 courses.

DRUG

cyclophosphamide

Cyclophosphamide IV over 30 minutes. Treatment repeats every 21 days for 3-8 courses.

DRUG

doxorubicin hydrochloride

Doxorubicin IV over 5 minutes. Treatment repeats every 21 days for 3-8 courses.

DRUG

prednisone

Oral prednisone on days 1-5. Treatment repeats every 21 days for 3-8 courses.

DRUG

vincristine sulfate

Vincristine IV over 5 minutes on day 1. Treatment repeats every 21 days for 3-8 courses.

GENETIC

microarray analysis

genetic testing

Trial Locations (1)

44106-7284

Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Case Comprehensive Cancer Center

OTHER

NCT00055640 - Molecular Risk Assessment in Planning Treatment for Patients With Non-Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter